Aurobindo Pharma’s Raleigh plant gets 'Voluntary Action Indicated' classification from US FDA

Aurobindo Pharma's US facility received a Voluntary Action Indicated classification. The US FDA closed its inspection of the Raleigh manufacturing plant. This classification allows applications for inhalers and other products to proceed. The inspection covered inhaler, dermatology, and transdermal product manufacturing operations. The company's regulatory filing confirmed the inspection closure and VAI status.